Compare AbbVie Inc (ABBV) vs Zscaler Inc (ZS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Zscaler Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Zscaler Inc trades at $143.6 (market cap $24.18B). The key difference: AbbVie Inc is far larger — about 18.6× Zscaler Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| ABBV | ZS | |
|---|---|---|
Market Cap | $449.91B | $24.18B |
Sector | Health | Technology |
52-Week High | $261.07 | $336.27 |
52-Week Low | $184.85 | $118.05 |
Enterprise Value | $513.38B | $22.50B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Zscaler (ZS) trades at $149.50, up 1.47% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Technical indicators show the stock trading near pivot point resistance at $149 with support at $145.
ZS presents a growth investment case with 79% analyst buy ratings and $192.64 consensus target, offering 29% upside. However, profitability challenges, ongoing class action investigations, and projected negative 2026 cash flow pose significant risks. The stock's high valuation multiples (P/S 7.53, EV/EBITDA 157.24) require sustained growth execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
